1 day-0.40%
1 week-0.40%
Current month-4.08%
1 month-6.79%
3 months-92.10%
6 months-95.11%
Current year-98.75%
1 month 0.47
Extreme 0.46600000
0.53
Current year 0.47
Extreme 0.46600000
47.8
1 year 0.47
Extreme 0.46600000
50.5
3 years 0.47
Extreme 0.46600000
141
5 years 0.47
Extreme 0.46600000
870
10 years 0.47
Extreme 0.46600000
2,300
Manager TitleAgeSince
Chief Executive Officer - 01/02/2024
Director of Finance/CFO 48 24/07/2025
Chief Executive Officer 74 -
Director TitleAgeSince
Director/Board Member 71 01/01/2021
Director/Board Member 59 01/01/2021
Chairman 46 14/06/2024
Change 5-day change 1-year change 3-year change Capi.($)
-0.40%-0.40% - - 143K
-2.49%-3.76%+53.38%+62.10% 63.66B
-0.63%-2.91%+6.55%+89.34% 58.56B
-2.37%-2.22%+21.77%+84.58% 54.19B
-2.19%-6.15%+12.43%+111.40% 44.66B
-1.89%-7.28%+9.30%+18.50% 40.51B
-0.93%-0.47%+19.34%+41.83% 36.27B
+1.11%-6.44%+127.46%+675.37% 34.87B
-0.80%+0.61%+76.27%+61.80% 32.26B
-2.17%+16.65%-28.89%+479.93% 31.01B
Average -1.28%-1.22%+33.07%+180.54% 44B
Weighted average by Cap. -1.48%-1.85%+31.83%+155.14%
Logo Biosergen AB
Biosergen AB is a Sweden-based biotechnology company. It carries out biopharmaceutical research and development through its Subsidiary Biosergen AS from laboratory facilities in Trondheim, Norway and several other places worldwide. The Company is developing BSG005, a potentially disruptive antifungal drug which has demonstrated safety and potency advantages over competing antifungals. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS, cancer and transplant patients every year. At equal dose levels BSG005 has demonstrated a three-to-fouold potency advantage against the relevant fungal strains compared to the current standard of care, while being completely free of the kidney toxicity hampering other drugs in its class.
Employees
1
  1. Stock Market
  2. Stocks
  3. BIOSGN Stock